74
Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review Michael E. Ruff, MD Dallas, Texas

Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

  • Upload
    asha

  • View
    38

  • Download
    0

Embed Size (px)

DESCRIPTION

Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review. Michael E. Ruff, MD Dallas, Texas. Photo: Personal collection, Dr. Dennis Williams Pharm.D. Effect of Inhaled Corticosteroids on Inflammation. E = Epithelium BM = Basement Membrane. - PowerPoint PPT Presentation

Citation preview

Page 1: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

Asthma – 2005

“Why We Do the Things We Do”

A Miniature Literature Review

Michael E. Ruff, MD

Dallas, Texas

Page 2: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 3: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 4: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 5: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 6: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 7: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 8: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 9: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 10: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 11: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 12: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 13: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 14: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 15: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 16: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

Photo: Personal collection, Dr. Dennis Williams Pharm.D.

Page 17: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 18: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 19: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 20: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 21: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 22: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 23: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 24: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 25: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 26: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 27: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 28: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 29: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 30: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 31: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 32: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 33: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 34: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 35: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 36: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 37: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 38: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 39: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 40: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 41: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 42: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 43: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 44: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 45: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

Effect of Inhaled Corticosteroids on Inflammation

Pre– and post–3-month treatment with budesonide (BUD) 600 mcg b.i.d.

E = Epithelium

BM = Basement Membrane

Laitinen et al. J Allergy Clin Immunol. 1992;90:32-42. Reprinted with permission.

Page 46: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 47: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 48: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 49: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

Mean Annual Increase in FEV1 During ICS Therapy

12

10

8

6

4

2

0

AnnualChange in

% PredictedFEV1

<2 2-3 3-5 >5

Asthma Duration at Start of ICS therapy (yrs)

Agertoft L, Pederson S. Respir Med. 1994; 88:373-381.

Page 50: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 51: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 52: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 53: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 54: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 55: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 56: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 57: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 58: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 59: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 60: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

Assessment of the Effects of Inhaled Corticosteroids on Growth

cm

0 1 2 3 4

Time (y)

0

130

135

140

150

160

145

155

Standing Height

*Children aged 5 to 12 years.Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343:1054-63.

Standing-Height Velocity

cm

/y

Time (y)0 1 2 3 4

0.0

4.5

5.0

5.5

6.5

6.0

Nedocromil PlaceboBudesonide

Page 61: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 62: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 63: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

Girls

Boys

Mea

sure

d A

dult

Hei

ght

(cm

)

Target Adult Height (cm)

200

190

180

170

160

150150 160 170 180 190 200

Effect of Long-term Treatment with Inhaled Budesonide on Adult Height in Children with Asthma

Agertoft L, Pedersen S. N Engl J Med. 2000;343:1064-1069.

Page 64: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 65: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 66: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 67: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

NIH Treatment Guidelines

NIH-preferred options are highlighted.

Guidelines for the Diagnosis and Management of Asthma. 2002.NIH Publication No. 02-5075.

• Step 1 - Mild Intermittent Asthma– No daily medication

• Step 2 - Mild Persistent Asthma– Low-dose inhaled corticosteroid (ICS)– Cromolyn/nedocromil, theophylline or leukotriene modifier

(alternative Rx)• Step 3 - Moderate Persistent Asthma

– Low to medium dose ICS + long-acting β2-agonist (LABA)– Medium-dose ICS – Low or medium ICS + LTRA or theophylline (alternative Rx)

• Step 4 - Severe Persistent Asthma– High-dose ICS + LABA– If needed, add oral steroids

Page 68: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 69: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 70: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 71: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 72: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review
Page 73: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

NIH Treatment Guidelines

NIH-preferred options are highlighted.

Guidelines for the Diagnosis and Management of Asthma. 2002.NIH Publication No. 02-5075.

• Step 1 - Mild Intermittent Asthma– No daily medication

• Step 2 - Mild Persistent Asthma– Low-dose inhaled corticosteroid (ICS)– Cromolyn/nedocromil, theophylline or leukotriene modifier

(alternative Rx)• Step 3 - Moderate Persistent Asthma

– Low to medium dose ICS + long-acting β2-agonist (LABA)– Medium-dose ICS – Low or medium ICS + LTRA or theophylline (alternative Rx)

• Step 4 - Severe Persistent Asthma– High-dose ICS + LABA– If needed, add oral steroids

Page 74: Asthma – 2005 “Why We Do the Things We Do” A Miniature Literature Review

• Teach and re-teach and re-check inhaler technique• Always assume that patients are poorly compliant,

especially if their asthma is poorly controlled • Monitor objective parameters of airway function (i.e.,

spirometry)• Assume that most asthmatics (and almost all children with

asthma) are allergic• Identify and counsel avoidance for triggering factors• Treat allergic rhinitis• Consider allergen-specific immunotherapy (i.e.,

allergy shots)• Realize that the natural history of persistent asthma is not

benign• Identify persistent asthmatics as early as possible and

institute treatment with anti-inflammatory agents• Monitor for drug side effects (e.g., plot growth curves), and

attempt to use the lowest effective therapeutic dose of inhaled corticosteroids